All News

How can pharmacists implement nonpharmacologic treatments for patients with dementia?

Advancements in targeted therapies have helped significantly improve survival in late-stage anaplastic lymphoma kinase positive non-small cell lung cancer.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.

Making the patients’ lives easier is at the heart of my job.

Top news of the week from Specialty Pharmacy Times.

Study finds that treating hepatitis C reduced the risk of developing the signs and symptoms of Parkinson disease.

A recall of Torrent Pharmaceuticals Limited’s Losartan Potassium Tablets USP has been expanded to include 8 additional lots. A total of 10 lots are now being recalled at the consumer level, including 2 recalled lots initially announced December 20, 2018.

New high-cost gene therapies are pushing health care providers to explore new methods to help the US health care system to fund specialty drugs.

The health insurance industry cautioned the Trump administration against allowing health reimbursement accounts (HRAs) to be used to purchase short-term limited duration health plans, in comments submitted regarding a proposed rule change.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Researches seeking to eliminate HIV are close enough to see the finish line, but with no idea how far away they are from a cure.

Transcranial direct current stimulation shows promise in addressing fatigue in patients with multiple sclerosis.

The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed.

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed.